鳞状细胞癌抗原在头颈癌患者随访中的应用
该回顾性分析纳入2010至2020年在荷兰Antoni van Leeuwenhoek医院治疗的789例头颈鳞状细胞癌患者,采用时间依赖Cox模型评估鳞状细胞癌抗原(SCC-Ag)与无事件生存(EFS)的关系。结果显示,二分类SCC-Ag(HR=3.01,95%CI:2.17-4.18)和SCC-Ag变化值(HR=1.15,95%CI:1.07-1.22)对EFS的预测优于累积平均值或当前值模型,在口咽癌亚组中变化值的关联更强(HR=4.88,95%CI:2.71-8.79)。
要点
- 二分类SCC-Ag预测EFS的HR=3.01(95%CI:2.17-4.18)。
- SCC-Ag变化值预测EFS的HR=1.15(95%CI:1.07-1.22)。
- 口咽癌亚组中SCC-Ag变化值的HR=4.88(95%CI:2.71-8.79)。
核心结论
- 二分类SCC-Ag值和SCC-Ag变化值可能是头颈鳞状细胞癌患者随访中预测无事件生存的重要标志物,这些结果在口咽癌患者中更明显。
研究设计与样本
- 回顾性分析,纳入2010至2020年在荷兰Antoni van Leeuwenhoek医院治疗的789例头颈鳞状细胞癌患者,至少有一次SCC-Ag测量,采用时间依赖Cox模型分析无事件生存。
主要发现
- 二分类SCC-Ag值预测EFS的HR=3.01(95%CI:2.17-4.18)。
- SCC-Ag变化值预测EFS的HR=1.15(95%CI:1.07-1.22)。
- 在调整肿瘤部位、分期、年龄和性别后,二分类SCC-Ag值和SCC-Ag变化值对EFS的预测仍优于使用累积平均值或当前值的模型。
- 在口咽癌亚组中,以SCC-Ag变化值作为线性预测因子观察到强关联(HR=4.88,95%CI:2.71-8.79)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: to determine if the tumor marker squamous cell carcinoma antigen (SCC-Ag) observed over time may contribute to the early detection of recurrence, metastasis, and second primary tumors in the follow-up of patients with head and neck squamous cell carcinoma (HNSCC). STUDY DESIGN: A retrospective analysis of patients with HNSCC and at least one SCC-Ag measurement was conducted. Hazard ratios (HRs) were used to determine the correlation between SCC-Ag and an event. SETTING: patients with HNSCC, treated in the Antoni van Leeuwenhoek Hospital in The Netherlands between 2010 and 2020 were used for the analysis. METHODS: Data from 789 patients were used on event-free survival (EFS) with time-dependent Cox models. In addition to current (most recent) SCC-Ag (also dichotomized into high and low as done for clinical practice), average SCC-Ag and change between SCC-Ag measurements (delta SCC-Ag) were considered, using restricted cubic splines to explore nonlinear relationships. RESULTS: Dichotomized SCC-Ag values (HR = 3.01, 95% confidence interval [CI]: 2.17-4.18) and the delta SCC-Ag (HR = 1.15, 95% CI: 1.07-1.22) predicted EFS better than models using the cumulative average or current value of SCC-Ag, also after adjusting for tumor site, stage, age, and gender. A strong association was observed when using delta SCC-Ag as a linear predictor in the subgroup of oropharynx patients (HR = 4.88, 95% CI: 2.71-8.79). CONCLUSION: Dichotomized and delta SCC-Ag values can be important markers for EFS, during the follow-up of patients treated for HNSCC. These results were more evident in patients with oropharyngeal cancer.
引用
- Schepens EJA, Al-Mamgani A, Karssemakers LHE, et al. Squamous Cell Carcinoma Antigen in the Follow-up of Patients With Head and Neck Cancer. Otolaryngol Head Neck Surg. 2023. PMID: 37694613. doi:10.1002/ohn.510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。